The invention provides dried microorganisms with increased shelf-life.

The invention provides dried microorganisms with increased shelf-life.

A method of mimicking a phenotype of a first ruminating animal in a second ruminating animal is disclosed. The method comprises administering to the second ruminating animal a microbial composition comprising a plurality of microbes having a signature which is statistically significantly similar to the microbial signature of a rumen microbiome of the first ruminating animal, wherein the first and the second ruminating animal are of identical species, thereby mimicking the phenotype of the first ruminating animal in the second ruminating animal.

A method of mimicking a phenotype of a first ruminating animal in a second ruminating animal is disclosed. The method comprises administering to the second ruminating animal a microbial composition comprising a plurality of microbes having a signature which is statistically significantly similar to the microbial signature of a rumen microbiome of the first ruminating animal, wherein the first and the second ruminating animal are of identical species, thereby mimicking the phenotype of the first ruminating animal in the second ruminating animal.

The present disclosure relates to a composition for preventing or treating metabolic diseases, in which the composition includes Bacteroides acidifaciens as an active ingredient. In addition, the present disclosure relates to a composition for oxidizing fat or inhibiting DPP-4, in which the composition includes Bacteroides acidifaciens as an active ingredient. In addition, the present disclosure relates to a transformant expressing a lean phenotype, in which an Atg7 gene is deleted in dendritic cells.

The present disclosure relates to a composition for preventing or treating metabolic diseases, in which the composition includes Bacteroides acidifaciens as an active ingredient. In addition, the present disclosure relates to a composition for oxidizing fat or inhibiting DPP-4, in which the composition includes Bacteroides acidifaciens as an active ingredient. In addition, the present disclosure relates to a transformant expressing a lean phenotype, in which an Atg7 gene is deleted in dendritic cells.

Disclosed are T-cell receptors (TCRs) binding to tumor-associated antigens (TAAs) for targeting cancer cells, T-cells expressing same, methods for producing same, and methods for treating cancers using same. Disclosed are TCRs and their variants that bind to HLA class I or II molecules with a peptide, such as MAG-003 have the amino acid sequence of KVLEHVVRV (SEQ ID NO:1). The description further relates to peptides, proteins, nucleic acids, cells for use in immunotherapeutic methods, the immunotherapy of cancer, and tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Disclosed are T-cell receptors (TCRs) binding to tumor-associated antigens (TAAs) for targeting cancer cells, T-cells expressing same, methods for producing same, and methods for treating cancers using same. Disclosed are TCRs and their variants that bind to HLA class I or II molecules with a peptide, such as MAG-003 have the amino acid sequence of KVLEHVVRV (SEQ ID NO:1). The description further relates to peptides, proteins, nucleic acids, cells for use in immunotherapeutic methods, the immunotherapy of cancer, and tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Provided are an Agathobaculum sp. strain having prophylactic or therapeutic effects on degenerative brain diseases, and use thereof. Since the intestinal microorganism Agathobaculum butyriciproducens SR79 strain of the present invention may have effects of inhibiting neuroinflammation and effects of improving movement regulation and cognitive and memory functions in animal models with degenerative brain diseases such as Parkinson's disease and Alzheimer's disease, the strain may be effectively used in foods, medicines, or feeds for preventing or treating brain diseases including Alzheimer's disease, Parkinson's disease, mild cognitive impairment, etc., and therefore, it is very useful in the relevant industries.

Provided are an Agathobaculum sp. strain having prophylactic or therapeutic effects on degenerative brain diseases, and use thereof. Since the intestinal microorganism Agathobaculum butyriciproducens SR79 strain of the present invention may have effects of inhibiting neuroinflammation and effects of improving movement regulation and cognitive and memory functions in animal models with degenerative brain diseases such as Parkinson's disease and Alzheimer's disease, the strain may be effectively used in foods, medicines, or feeds for preventing or treating brain diseases including Alzheimer's disease, Parkinson's disease, mild cognitive impairment, etc., and therefore, it is very useful in the relevant industries.